Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/9640
Title: | Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes. | Austin Authors: | Bonnet, Fabrice;Cao, Zemin;Cooper, Mark E;Cox, Allison J;Kelly, D J;Gilbert, Richard E | Affiliation: | Department of Medicine, University of Melbourne, Austin & Repatriation Medical Centre, Heidelberg West, Victoria. fab.so.bonnet@free.fr | Issue Date: | 1-Sep-2003 | Publication information: | Diabetes & Metabolism; 29(4 Pt 1): 386-92 | Abstract: | The growth factors transforming growth factor-B (TGF-B) and epidermal growth factor (EGF) have both been implicated in the hypertrophic structural changes in the vasculature that are characteristic features of both human and experimental diabetes. Recently, tranilast (N(3,4-dimethoxycinnamoyl)anthranilic acid), a drug used in the treatment of allergic and dermatological diseases, has also been reported to inhibit transforming growth factor-B (TGF-B)-mediated collagen formation. However, its effects on vascular hypertrophy in diabetes are unknown. The present study thus sought to determine the effects of tranilast on both TGF-B and EGF expression and mast cells in mediating the trophic vascular changes in experimental diabetes.Vessel morphology, growth factors and collagen gene expression and matrix deposition were examined in the mesenteric arteries of control rats treated with or without tranilast, and streptozotocin-induced diabetic Sprague-Dawley rats treated with or without tranilast (200 mg/kg/day) during a 3-week period.Compared with control animals, diabetic rats had significantly increased vessel weight, wall: lumen ratio, ECM accumulation, gene expression of TGF-B1, EGF, and both alpha1 (I) and alpha1 (IV) collagen. Tranilast treatment did not influence plasma glucose or systemic blood pressure. However, tranilast significantly reduced mesenteric weight, wall: lumen ratio and matrix deposition and also attenuated the overexpression of TGF-B1, EGF, and both alpha1 (I) and alpha1 (IV) collagen mRNA in diabetic rats.These findings indicate that tranilast ameliorates pathological vascular changes observed in experimental diabetes in association with reduced growth factor expression independent of blood glucose or systemic blood pressure. | Gov't Doc #: | 14526266 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/9640 | Journal: | Diabetes & metabolism | URL: | https://pubmed.ncbi.nlm.nih.gov/14526266 | Type: | Journal Article | Subjects: | Animals Base Sequence Blood Vessels.drug effects.pathology Collagen.genetics DNA Primers Diabetes Mellitus, Experimental.complications Diabetic Angiopathies.prevention & control Epidermal Growth Factor.genetics Gene Expression Regulation.drug effects Growth Substances.genetics.metabolism Hypertrophy Immunohistochemistry Male Platelet Aggregation Inhibitors.therapeutic use Rats Rats, Sprague-Dawley Reverse Transcriptase Polymerase Chain Reaction Transforming Growth Factor beta.genetics ortho-Aminobenzoates.therapeutic use |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.